장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킴(노출되어도 특정 표적장기 독성을 일으키지 않는다는 결정적인 노출경로가 있다면 노출경로를 기재)
특정 표적장기 독성 - 1회 노출
구분 1
위험
P260, P264, P270, P307+P311, P321,P405, P501
예방조치문구:
P210
열·스파크·화염·고열로부터 멀리하시오 - 금연 하시오.
P260
분진·흄·가스·미스트·증기·...·스프레이를 흡입하지 마시오.
P280
보호장갑/보호의/보안경/안면보호구를 착용하시오.
P301+P310
삼켰다면 즉시 의료기관(의사)의 진찰을 받으시오.
P311
의료기관(의사)의 진찰을 받으시오.
트리아졸람 C화학적 특성, 용도, 생산
화학적 성질
Yellow Solid
용도
Triazolam
World Health Organization (WHO)
Triazolam, a benzodiazepine derivative with sedative and
hypnotic activity, was introduced in 1978 for themanagement of insomnia. It is
controlled under Schedule IV of the 1971 Convention of Psychotropic Substances.
Concern regarding the psychotropic effects of triazolam was first raised in the
Netherlands in 1979 when this compound was suspended for sale and
subsequently withdrawn by the Committee for the Evaluation of Medicines on the
basis of reports of a reversible complex of symptoms including paranoia,
depersonalization, nightmares, suicidal tendency and hyperaesthesia in patients
receiving the drug. The basis for this decision was later successfully contested by
the manufacturer and the drug was reregistered in early 1990 with a revised
product information. However, concern was regenerated elsewhere that higher
doses are associated with an unacceptable incidence of unwanted effects and the
manufacturer has eventually withdrawn 0.5 mg tablets on a worldwide basis. In 1991 the issue of the safety of triazolam was again reopened by reports of
retrograde amnesia and depression among patients taking the decreased
recommended dosages. The product information has been revised by the United
States FDA to include more rigorous cautions regarding dosage. In the Member
States of the European Communities the products have been suspended pending
further review by the EC Committee on Proprietary Medicinal Products.
일반 설명
Triazolam, 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4] benzodiazepine(Halcion), has all of the characteristic benzodiazepine pharmacologicalactions. It is an ultra–short-acting hypnoticbecause it is rapidly α-hydroxylated to the 1-methyl alcohol,which is then rapidly conjugated and excreted.Consequently, it has gained popularity as sleep inducers, especiallyin elderly patients, because it causes less daytimesedation. It is metabolically inactivated primarily by hepaticand intestinal CYP3A4; therefore, coadministration withgrapefruit juice increases its peak plasma concentration by30%, leading to increased drowsiness.
